Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
Date:8/31/2007

DETROIT, Aug. 31 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd., (Amex: CPD) announced today that the US Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Allopurinol Tablets USP, 100 mg and 300 mg (Allopurinol).

Allopurinol is indicated in the management of patients with signs and symptoms of primary or secondary gout, the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels, the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion are elevated. Our generic Allopurinol is the bioequivalent to Zyloprim(R), a registered trademark of Prometheus Laboratories, Inc. According to IMS Data, for the twelve months ended June 2007, Allopurinol generic and brand products (Zyloprim(R)) combined had annual sales of approximately $33 million.

Daniel H. Movens, Caraco's Chief Executive Officer, said, "We are pleased to gain this approval from the FDA. Our focus continues to be working towards expanding our product line effectively, including products that are already available generically in the market that potentially can add measurable value. We plan to market this product to the generic pharmaceutical market immediately. This will bring our total product selection to 38 different products represented by 78 various strengths."

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or cheaper products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward- looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. South Africa Wins landmark case against pharmaceutical giants
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Setting up a new pharmaceutical industry in India
5. Medicis Pharmaceutical company enters pediatric market
6. Supply of Radiopharmaceuticals Hampered by Attacks
7. Pharmaceutical companies are targeting patients
8. FDA approves Watson Pharmaceuticals Oxytrol patch
9. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
10. Indian Pharmaceutical Industries Stops Manufacturing And Sale Of Valdecoxib
11. Pharmaceutical industries grant for R&D to be monitored
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... California (PRWEB) , ... February 09, 2016 , ... ... students, faculty and staff helped give free oral screenings to 150 children in ... 5, 2016. , The College of Dental Medicine joined Chinese American Dental Society ...
(Date:2/9/2016)... Fort Lauderdale, Florida (PRWEB) , ... February 09, 2016 , ... ... known as the Taste of South Florida Event, an upscale fundraiser held in South ... to wow sponsors and guests alike. This year the event will be held in ...
(Date:2/9/2016)... MA (PRWEB) , ... February 09, 2016 , ... ... (WCRI) compares the workers’ compensation fee schedule rates and Medicare rates for a ... services covered in the report, Evaluation of the 2015 Fee Schedule Rates ...
(Date:2/9/2016)... ... February 09, 2016 , ... On January 12, 2016 Paul McElwee, a ... they noticed their furnace not producing any heat. Shortly after entering the home, Paul ... exchanger was leaking dangerous levels of carbon monoxide into the home, at 2,000 parts ...
(Date:2/9/2016)... ... February 09, 2016 , ... METTLER TOLEDO ... lab personnel have a basic understanding of the techniques they use so they ... will help them reduce waste and rework to create a leaner overall lab ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... February 10, 2016 The campaign aims ... 5 years reach the milestone of their 5 th ... ensure 2,50,532 children between the ages of 2 - 5 ... --> The campaign aims to ... reach the milestone of their 5 th birthday   ...
(Date:2/9/2016)... 9, 2016  Insulet Corporation (NASDAQ: PODD ) (Insulet ... technology with its OmniPod ® Insulin ... has been appointed to Insulet,s Board of Directors. With his ... of whom are independent. --> ... and finance experience and a deep knowledge of accounting, financial ...
(Date:2/9/2016)... QGEN ; Frankfurt Prime ... Genomics to develop and promote comprehensive solutions for ... --> QGEN ; Frankfurt Prime Standard: QIA) ... develop and promote comprehensive solutions for next-generation sequencing ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ...
Breaking Medicine Technology: